Medical therapy with alpha-blockers in prostatic hypertrophy is indicated during the irritative stage or when there is modest obstruction; careful patient selection is therefore fundamental. The molecules available and the absolute and relative counter-indications are reviewed.
PennisiM.: Impiego degli α-litici nella terapia dell'ipertrofia prostatica benigna non complicata. Acta Urologica Mediterranea, 1: 6, 1985.
2.
CucchiA.: Bladder out-flow obstruction and detrusor contraction speed in benign prostatic hyperplasia. Urodinamica, 1 (1): 39–43, 1991.
3.
JardinA., LeporH.: The α-blockers in the treatment of BPH. Proceedings of the International Consultation on Benign Prostatic Hyperplasia. Paris, 163–74, 1991.
4.
) Committae 9: α-blockers in the treatment of BPH: recommendations of committee. Proceedings of the International Consultation on Benign prostatic Hyperplasia. Paris, 175–6, 1991.
5.
ChristmasT.J., KirbyR.S.: Alpha-adrenoreceptor blockers in the treatment of benign prostatic hyperplasia. World Journal of Urology, 9 (1): 36–40, 1991.
6.
CaineM.: Patient responders with alpha-blockade. Research and practice developments in BPH. Spring 4, 1992.
7.
ShapiroE.: Selective alpha-1 blockers: efficacy versus side effects. Research and practice developments in BPH. Spring, 7, 1992.
8.
HaldeT., NielsenK.K., NordlingJ.: Clinical urodynamics in benign prostatic hyperplasia. European Urology Update Series, 2 (10), 74–79, 1993.
9.
ChappieC.R.: Role of alpha adrenergic blocking drugs in the treatment of bladder outflow obstruction. European Urology Update Series, 2 (21): 162–167, 1993.
10.
CaìneA.: Alpha blockers for BPH. The prostate: advances in pathophysiology, diagnosis and treatment of benign and malignant diseases. Erice (Italy), 1993.
11.
HabenichtU.F.: Aromatase inhibitors and benign prostatic hyperplasia: chance and limitation. The prostate: advances in pathophysiology, diagnosis and treatment of benign and malignant diseases. Erice (Italy), 1993.
12.
KazukiKawabe: Effect and safety of Tamsulosin in the treatment of benign prostatic hyperplasia. Atti 23° Congresso mondiale SIU, Sydney, 315, 1994.
13.
LeporH.: Alpha 1 receptor selectivity: clinical or theoretical benefit? Atti 23° congresso mondiale SIU, Sydney, 315, 1994.
